Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Helix BioPharma ( (TSE:HBP) ).
Helix BioPharma Corp. has successfully closed a non-brokered private placement of 2,222,333 common shares, raising $1,666,750. This marks the second phase of their bridge financing strategy aimed at securing larger institutional investment and uplisting on NASDAQ. The funds will support near-term development activities and working capital as Helix continues discussions with institutional investors.
Spark’s Take on TSE:HBP Stock
According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Underperform.
Helix BioPharma faces significant financial challenges with no revenue and continuous losses, resulting in a low financial performance score. Weak market momentum and poor valuation metrics further dampen the stock’s attractiveness. Recent corporate events provide some strategic hope, but are not enough to overcome the fundamental financial issues.
To see Spark’s full report on TSE:HBP stock, click here.
More about Helix BioPharma
Helix BioPharma is an oncology company focused on developing innovative therapies for hard-to-treat cancers. Their pipeline includes Tumor Defense Breaker™ L-DOS47, an antibody-enzyme conjugate for non-small cell lung cancer, and other advanced cancer treatment candidates such as LEUMUNA™ and GEMCEDA™.
Average Trading Volume: 10,422
Technical Sentiment Signal: Hold
Current Market Cap: C$102.3M
For an in-depth examination of HBP stock, go to TipRanks’ Overview page.